Landmark clinical trial of a novel combination treatment for type 1 diabetes

(McGill University) Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes. The treatment combines INGAP Peptide (ExsulinTM), which stimulates growth of the insulin secreting islets, and ustekinumab (SteleraTM), a drug approved for the treatment of psoriasis.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news